# Loading Dose or Standard Dose of Intravenous Ibandronate in Treating Patients With Lung Cancer and Skeletal Metastasis

> **NCT00492843** · PHASE4 · TERMINATED · sponsor: **Chinese Society of Lung Cancer** · enrollment: 20 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Ibandronate (Bondronat)

## Key facts

- **NCT ID:** NCT00492843
- **Lead sponsor:** Chinese Society of Lung Cancer
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-07
- **Primary completion:** 2008-01
- **Final completion:** 2008-07
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** It is too difficult to recruit suitable patients.
- **Last updated:** 2016-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00492843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00492843, "Loading Dose or Standard Dose of Intravenous Ibandronate in Treating Patients With Lung Cancer and Skeletal Metastasis". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00492843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*